Geistlich Derma-Gide®
Evidence Supporting Geistlich Derma-Gide®
Clinically Proven | Cost Effective
When it comes to the safety and quality of its products…Geistlich does not compromise.
Decades of experience with biomaterials and pioneering work achieved are documented in meaningful scientific evidence. Here is a look at Geistlich’s ever growing scientific and clinical body of evidence for Geistlich Derma-Gide® published in world-renowned and prestigious global journals. Watch or read for yourself . . .
Armstrong, David G. et al. “Use of a Purified Reconstituted Bilayer Matrix (PRBM) in the Management of Chronic Diabetic Foot Ulcers Improves Patient Outcomes vs Standard of Care – Results of a Prospective Randomized Controlled Multi-Center Clinical Trial”. International Wound Journal, 2022; 1-13. Wiley, https://doi.org/10.1111/iwj.13715
Highlights:
- 85% (intent to treat; p-value 0.0004 [N = 40]) and 94% (per protocol; p-value 0.00008 [N = 37]) healing rates with Geistlich Derma-Gide® vs 30% for SOC
- Mean healing time of 36.8 days for Geistlich Derma-Gide® vs 66.5 days for SOC
- Mean cost of healing of $1,731 for Geistlich Derma-Gide®
Armstrong, David G. et al. “Functional Properties Of A Purified Reconstituted Bilayer Matrix Design Support Natural Wound Healing Activities”. Plastic and Reconstructive Surgery–Global Open, vol 9, no. 5, 2021, p. E3596. Ovid Technologies (Wolters Kluwer Health), https://doi.org/10.1097/gox.0000000000003596
Highlights:
- Geistlich Derma-Gide® provides an optimized structure for cell migration and attachment.
- Growth factors bind to Geistlich Derma-Gide® and are preserved in an active state over time, while excessive MMP activity can be modulated.
- This in vitro data supports the promising healing rate observed clinically.
Armstrong, David G. “An Observational Pilot Study Using A Purified Reconstituted Bilayer Matrix To Treat Non-Healing Diabetic Foot Ulcers”. International Wound Journal, vol 17, no. 4, 2020, pp. 966-973. Wiley, https://doi.org/10.1111/iwj.13353
Highlights:
- At study conclusion, complete wound closure was achieved for 90% of the wounds (9/10 patients).
- Average time to complete wound closure was 2.7 weeks with an average wound size of 3.3cm2.
- The average cost to treat the patients in the cohort was $1,203.
CAUTION: This product is only available in the U.S.A. Federal (U.S.A.) law restricts these devices to sale by or on the order of a physician.